LoadingLoadingLoadingNet selling: insiders sold $5.4M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (1)
Point72
$61.8M
added
Sells/Trims (2)
Viking Global
$81.2M
sold
Millennium
$64.2M
trimmed
No tracked top-trader positions in WST as of Oct 24, 04:45 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Jul 23, 2026
Financial period
Q2 2026
Earnings per share
$2.08 expected
Revenue
Company release
Q3 2026 guidance
$820.0M to $835.0M
No comparable estimate
Estimates as of Oct 24, 2026
EPS expected
$2.16 to $2.23
Revenue expected
12 analysts
Last 30 days
Analysts raising estimates
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 23, 2026 | $2.37 / $2.08Yahoo Finance | +13.86% beat | $872.3M No estimate | Unavailable |
| Mar 31, 2026 | Apr 23, 2026 | $2.13 / $1.68Yahoo Finance | +27.07% beat | $844.9M No estimate | Unavailable |
| Dec 31, 2025 | Feb 12, 2026 | $2.04 / $1.83Yahoo Finance | +11.54% beat | $805.0M No estimate | Unavailable |
| Sep 30, 2025 | Oct 23, 2025 | $1.96 / $1.71Yahoo Finance | +14.55% beat | $804.3M No estimate | Unavailable |
| Jun 30, 2025 | Jul 24, 2025 | $1.84 / $1.54Alpha Vantage | +19.48% beat | $766.2M No estimate | Unavailable |
| Mar 31, 2025 | Apr 24, 2025 | $1.45 / $1.26Alpha Vantage | +15.08% beat | $698.2M No estimate | Unavailable |
| Dec 31, 2024 | Feb 13, 2025 | $1.82 / $1.71Alpha Vantage | +6.43% beat | $748.5M No estimate | Unavailable |
| Sep 30, 2024 | Oct 24, 2024 | $1.85 / $1.49Alpha Vantage | +24.16% beat | $746.9M No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $804.3M | $805.0M | $844.9M | $872.3M |
| Cost of what it sold | $510.8M | $501.1M | $548.5M | $543.1M |
| Gross profit | $293.5M | $303.9M | $296.4M | $329.2M |
| What it spent | ||||
| Research and development | $17.1M | $21.8M | $15.8M | $19.7M |
| Sales and admin | $102.7M | $106.5M | $99.5M | $117.6M |
| Other operating costs | — | $18.5M | $4.0M | $12.8M |
| Total operating expenses | $119.8M | $146.8M | $119.3M | $150.1M |
| What was left | ||||
| Operating profit | $173.7M | $156.6M | $177.1M | $179.1M |
| Interest on debt | $100.0K | $5.3M | $1.9M | $2.6M |
| Profit before tax | $174.0M | $165.4M | $180.1M | $180.1M |
| Tax | $34.0M | $33.3M | $44.7M | $32.2M |
| Net profit | $140.0M | $132.1M | $138.8M | $154.0M |
| EBITDA | $217.1M | $209.5M | $218.5M | $225.3M |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Wingstop, Inc. Estimates – MUN:WST
NeutralOct 23West Pharmaceutical Services, Inc. Estimates – BOATS:WST
NeutralOct 23West Pharmaceutical Services (WST) Lifts Its Dividend, Is The Stock Fully Priced?
Leans bullishOct 22Penumbra, Inc. (PEN) Stock forecasts
BullishOct 22West Pharmaceutical Services Inc Unsponsored Brazilian Depositary Receipt Repr 0.0285714 Sh
NeutralOct 21Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
BullishOct 21West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day
BullishOct 21West Pharmaceutical Services, I (WST) Stock Forecasts
BullishOct 2132 macro signals shaping WST right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
